The anti-cardiac antibodies cross-reacting with the Streptococcal membranes were studied by the method of Zabriskie and co-authors in 162 patients with rheumatism in its active phase and in 181 control individuals. The anti-cardiac antibodies were found in over half of the rheumatic patients and far less frequently in the controls. At the same time in the majority of cases only those anti-cardiac antibodies that were found in the rheumatics possessed distinct cross-activity towards the A-streptococcal membranes. Most consistently were they found in those with a protracted course of the disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Post-COVID Myocarditis in Patients with Primary Cardiomyopathies: Diagnosis, Clinical Course and Outcomes.
Genes (Basel)
August 2024
Laboratory of Medical Genetics, B.V. Petrovsky Russian Research Center of Surgery, 119991 Moscow, Russia.
Article Synopsis
- The study investigated post-COVID myocarditis in 10 patients with various cardiomyopathies (CMPs) following COVID-19 infection, focusing on their clinical outcomes.
- A range of CMPs were identified in the patients, including left ventricular non-compaction, dilated cardiomyopathy, and AL cardiac amyloidosis, with all undergoing detailed cardiac evaluations.
- Post-COVID myocarditis was confirmed in six patients, showing improvements in heart function when treated with immunosuppressive corticosteroids; this highlighted the importance of monitoring arrhythmias and heart failure in CMP patients after COVID-19.
Diagnosis and treatment of myocarditis can be challenging, including determining indications for heart transplantation. We present a 6-year medical history of a 54 years old patient with severe morphologically verified viral-negative lymphocytic myocarditis and systemic manifestations (onset of hemorrhagic vasculitis) combined with moderate coronary atherosclerosis, which regressed according to repeated coronary angiography. For 5 years, the patient received immunosuppressive therapy with methylprednisolone and azathioprine with a significant improvement.
View Article and Find Full Text PDFSintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report.
Front Immunol
November 2023
Department of Neurology, Jiangdu People's Hospital affiliated to Yangzhou University, Yangzhou, China.
The use of immune checkpoint inhibitors (ICIs) has shown remarkable efficacy in the treatment of various malignancies, significantly reshaping cancer treatment. However, as a result of the widespread use of ICIs, several immune-related adverse events (iRAEs) have emerged, some of which can be rare and potentially fatal. In this paper, we reported the earliest case of Sintilimab used in the treatment of esophageal cancer with severe inflammatory myopathy (involving the cardiac, respiratory, and skeletal muscles)in China.
View Article and Find Full Text PDFMyricetin ameliorates experimental autoimmune myocarditis in mice by modulating immune response and inhibiting MCP-1 expression.
Eur J Pharmacol
March 2023
Department of Clinical Laboratory, Key Clinical Laboratory of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Electronic address:
Myocarditis is defined as an inflammatory disease of the myocardium, and the autoimmune response specific to myocardium plays an important role in chronic myocarditis. Inhibiting myocardial-specific autoimmune response and inflammation is crucial to treat myocarditis. Myricetin is a plant-derived flavonoid in nature which has potent anti-inflammatory and cardiovascular protective properties.
View Article and Find Full Text PDFThe majority of severe COVID-19 patients develop anti-cardiac autoantibodies.
Geroscience
October 2022
Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Severe cases of COVID-19 are characterized by an inflammatory burst, which is accompanied by multiorgan failure. The elderly population has higher risk for severe or fatal outcome for COVID-19. Inflammatory mediators facilitate the immune system to combat viral infection by producing antibodies against viral antigens.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!